Bempedoic Acid Pregnancy Surveillance Program

Launched by ESPERION THERAPEUTICS, INC. · Oct 21, 2021

Keywords

ClinConnect Summary

The Bempedoic Acid Pregnancy Surveillance Program is a clinical trial designed to learn more about the effects of bempedoic acid, a medication used to lower cholesterol, during pregnancy. This study is important because it aims to gather information about the safety and outcomes of using this medication in pregnant women. The trial is currently recruiting female participants who have taken at least one dose of bempedoic acid or a combination of bempedoic acid with another medication called ezetimibe at any point during their pregnancy.

If you are a woman who has been pregnant and has used bempedoic acid, you may be eligible to participate in this study. Participants will be asked to share information about their pregnancy and any experiences they had while taking the medication. This is a great opportunity to contribute to important research that could help other pregnant women in the future. Your participation will help researchers understand how this medication affects pregnancy outcomes, which is valuable information for both healthcare providers and patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome
• Exclusion Criteria: